Novartis Vs Roche

Roche eyes quick FDA approval of risdiplam for spinal muscular atrophy

The US Food and Drug Administration granted priority review for risdiplam, an oral medicine for those with the potentially deadly muscle-wasting disorder

Updated On: 25 Nov 2019 | 8:23 PM IST

Novartis' skin cancer drug posts win in trials, Roche flops

Novartis's mix of Tafinlar and Mekinist slashed the risk of melanoma returning or death by 53%

Updated On: 11 Sep 2017 | 12:16 PM IST